Thread by @M_SuarezCalvet

Our new paper in paper in blood 🩸 and CSF p-tau in #preclinical #Alzheimers 🧠 is out in @EmboMolMed ‼️

A great collaboration between #BarcelonaBeta @fpmaragall and @goteborgsuni

1/n

embopress.org/doi/full/10.15…

A collaboration between great scientists!

@TommyKakari @NicholasAshton @Marta_Mila_ @JuandoGispert @gesalbla @CarolinaMingui2 @ArenazaEider @GSBenavides and all the team of #BarcelonaBeta and the Blennow/Zetterberg lab in @goteborgsuni

A summary below

2/n

We investigated novel CSF and plasma p‐tau biomarkers in the preclinical stage of the Alzheimer’s continuum and compared them with the widely used CSF Mid‐p-tau181.

We hypothesized that they change when subtle changes in Aβ are detectable.

3/n

We show that the novel CSF N‐p‐tau181, N‐p‐tau217 and Mid‐p‐tau231:

👉 increase more prominently early in the continuum
👉 increase with subthreshold levels of Aβ pathology
👉 can more accurately differentiate Aβ‐positive CU individuals from those that are Aβ‐negative

4/n

We also show that the novel plasma 🩸 N‐p‐tau181 significantly increases 📈 in the preclinical stage of the #Alzheimers continuum

although the magnitude of that increase is not as high as that of the CSF p‐tau biomarker

5/n

Model of the changes of p-tau biomarkers as a function of #amyloid pathology (CSF o PET) in #preclinical #Alzheimers : 📈